For: | Ierardi E, Losurdo G, Fortezza RFL, Principi M, Barone M, Leo AD. Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness. World J Gastroenterol 2019; 25(34): 5097-5104 [PMID: 31558859 DOI: 10.3748/wjg.v25.i34.5097] |
---|---|
URL: | https://www.wjgnet.com/1009-3079/full/v25/i34/5097.htm |
编号 | Citing Articles |
1 |
Enzo Ierardi, Giuseppe Losurdo, Alessia Mileti, Rosa Paolillo, Floriana Giorgio, Mariabeatrice Principi, Alfredo Di Leo. The Puzzle of Coccoid Forms of Helicobacter pylori: Beyond Basic Science. Antibiotics 2020; 9(6): 293 doi: 10.3390/antibiotics9060293
|
2 |
Seokin Kang, Yuri Kim, Ji Yong Ahn, Hwoon-Yong Jung, Nayoung Kim, Hee Kyong Na, Jeong Hoon Lee, Kee Wook Jung, Do Hoon Kim, Kee Don Choi, Ho June Song, Gin Hyug Lee. Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting. Antibiotics 2021; 10(2): 214 doi: 10.3390/antibiotics10020214
|
3 |
Angela B. Muñoz, Johanna Stepanian, Alba Alicia Trespalacios, Filipa F. Vale. Bacteriophages of Helicobacter pylori. Frontiers in Microbiology 2020; 11 doi: 10.3389/fmicb.2020.549084
|
4 |
Muhammad Miftahussurur, Boby Pratama Putra, Yoshio Yamaoka. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals 2020; 13(10): 276 doi: 10.3390/ph13100276
|
5 |
Yu‐Zhen Wang, Jie Chen, Shi‐Qin Pei, Chen Wang, Gang Han, Lian‐Di Kan, Liu‐Cheng Li. Treatment strategies and pharmacist‐led medication management for Helicobacter pylori infection. Drug Development Research 2023; 84(2): 326 doi: 10.1002/ddr.22025
|
6 |
Anthony O'Connor, Takahisa Furuta, Javier P. Gisbert, Colm O'Morain. Review – Treatment of Helicobacter pylori infection 2020. Helicobacter 2020; 25(S1) doi: 10.1111/hel.12743
|
7 |
V.I. Petrov, A.V. Ponomareva, I.V. Ivakhnenko, O.V. Razvalyaeva, A.M. Dotsenko. PROBLEMS OF ERADICATION THERAPY AND WAYSTO OVERCOME THEM: REVIEW OF MODERN RECOMMENDATIONS AND REAL PRACTICE. Journal of Volgograd State Medical University 2022; 19(4): 22 doi: 10.19163/1994-9480-2022-19-4-22-33
|
8 |
Diego Reyes, Javier Ortiz, Eduardo Fuentes-López, Sigall Budnik, Vicente Gándara, Andrea Gallardo, María Francisca Seydewitz, Roberto Candia, José Ignacio Vargas, María Paz Rollan, Javiera Godoy, Antonio Rollan, Rodrigo Mansilla, Alex Arenas, Javier Chahuán, Alberto Espino, Margarita Pizarro, Arnoldo Riquelme. Terapias cuádruples son superiores a terapia triple estándar en primera línea de erradicación de Helicobacter pylori en Chile. Gastroenterología y Hepatología 2022; 45(7): 515 doi: 10.1016/j.gastrohep.2021.11.010
|
9 |
Seokin Kang, Nam-Hoon Kim, Seokhyeon Jeong, Jong Wook Kim, Jung Rock Moon, Yoon Suk Lee, Jun Hyuk Son. Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Helicobacter pylori Eradication. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2024; 24(2): 168 doi: 10.7704/kjhugr.2024.0012
|
10 |
Zhaoshi Bai, Nianyang Ding, Jianjuan Ge, Yue Wang, Lei Wang, Nan Wu, Qing Wei, Silu Xu, Xiaolin Liu, Guoren Zhou. Esomeprazole overcomes paclitaxel‐resistance and enhances anticancer effects of paclitaxel by inducing autophagy in A549/Taxol cells. Cell Biology International 2021; 45(1): 177 doi: 10.1002/cbin.11481
|
11 |
Seyed Mohammad Valizadeh Toosi, Sahar Feyzi, Arash Kazemi. Comparison of the Efficacy of 12-day Concomitant Quadruple Therapy versus 14-day High dose Dual Therapy as a First-line H. pylori Eradication Regimen. The Korean Journal of Gastroenterology 2024; 83(4): 150 doi: 10.4166/kjg.2024.012
|
12 |
Vladimir Milivojevic, Ivana Babic, Dusan Kekic, Ivan Rankovic, Sabir Sagdati, Nikola Panic, Izabela Sekulic Spasic, Miodrag Krstic, Tomica Milosavljevic, Leticia Moreira, Olga Perez Nyssen, Francis Mégraud, Colm O’ Morain, Javier Gisbert. Current Trends in the Management of Helicobacter pylori Infection in Serbia: Preliminary Results from the European Registry on H. pylori Management. Digestive Diseases 2023; 41(3): 377 doi: 10.1159/000528389
|
13 |
Dicky Pranantyo, Kaixi Zhang, Zhangyong Si, Zheng Hou, Mary B. Chan-Park. Smart Multifunctional Polymer Systems as Alternatives or Supplements of Antibiotics To Overcome Bacterial Resistance. Biomacromolecules 2022; 23(5): 1873 doi: 10.1021/acs.biomac.1c01614
|
14 |
Giuseppe Losurdo, Ilaria Lacavalla, Francesco Russo, Giuseppe Riezzo, Irene Brescia, Maria Rendina, Enzo Ierardi, Alfredo Di Leo. Empiric “Three-in-One” Bismuth Quadruple Therapy for Second-Line Helicobacter pylori Eradication: An Intervention Study in Southern Italy. Antibiotics 2022; 11(1): 78 doi: 10.3390/antibiotics11010078
|
15 |
Sarita Ratana‐Amornpin, Likasith Sanglutong, Thanee Eiamsitrakoon, Sith Siramolpiwat, David Y. Graham, Varocha Mahachai. Pilot studies of vonoprazan‐containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan. Helicobacter 2023; 28(6) doi: 10.1111/hel.13019
|
16 |
Yan Hay Grace Lee, Nicole T. Cerf, Nicholas Shalaby, Mónica R. Montes, Ronald J. Clarke. Bioinformatic Study of Possible Acute Regulation of Acid Secretion in the Stomach. The Journal of Membrane Biology 2024; 257(1-2): 79 doi: 10.1007/s00232-024-00310-7
|
17 |
Qing Liu, Yan Song, Ruonan Wang, Jinwei Sun, Jian He, Qiming Li, Guofang Zhang, Xinkai Ma, Chun Li, Libo Liu. Inhibition of Helicobacter pylori by Lactobacillus rhamnosus L08 in combination with Curcuma longa extracts. Food Bioscience 2024; 59: 104129 doi: 10.1016/j.fbio.2024.104129
|
18 |
Ligang Liu, Milap C. Nahata. Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of Helicobacter pylori Infection. Annals of Pharmacotherapy 2023; 57(10): 1185 doi: 10.1177/10600280221149708
|
19 |
Ahmed Kamal, Ramy Mohamed Ghazy, Dalia Sherief, Aliaa Ismail, Walid Ismail Ellakany. Helicobacter pylori eradication rates using clarithromycin and levofloxacin-based regimens in patients with previous COVID-19 treatment: a randomized clinical trial. BMC Infectious Diseases 2023; 23(1) doi: 10.1186/s12879-023-07993-8
|
20 |
Pedro Cortés, Alfred D. Nelson, Yan Bi, Fernando F. Stancampiano, Loren P. Murray, George G.A. Pujalte, Victoria Gomez, Dana M. Harris. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. Journal of Primary Care & Community Health 2021; 12: 215013272110140 doi: 10.1177/21501327211014087
|
21 |
Paulius Jonaitis, Juozas Kupcinskas, Olga P. Nyssen, Ignasi Puig, Javier P. Gisbert, Laimas Jonaitis. Evaluation of the Effectiveness of Helicobacter pylori Eradication Regimens in Lithuania during the Years 2013–2020: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg). Medicina 2021; 57(7): 642 doi: 10.3390/medicina57070642
|
22 |
Pranjal Kumar Singh, T.S. Easwari. Emerging Trends and their Impacts on Peptic Ulcer Diseases: Treatments
and Techniques. Current Drug Therapy 2022; 17(1): 2 doi: 10.2174/1574885517666220307115813
|
23 |
Diego Reyes, Javier Ortiz, Eduardo Fuentes-López, Sigall Budnik, Vicente Gándara, Andrea Gallardo, María Francisca Seydewitz, Roberto Candia, José Ignacio Vargas, María Paz Rollan, Javiera Godoy, Antonio Rollan, Rodrigo Mansilla, Alex Arenas, Javier Chahuán, Alberto Espino, Margarita Pizarro, Arnoldo Riquelme. Quadruple therapies are superior to standard triple therapy for Helicobacter pylori first-line eradication in Chile. Gastroenterología y Hepatología (English Edition) 2022; 45(7): 515 doi: 10.1016/j.gastre.2022.07.004
|
24 |
Chao Ran Ji, Jing Liu, Yue Yue Li, Chen Qiao, Jun Yan Qu, Jun Nan Hu, Min Juan Lin, Rui Ji, Li Xiang Li, Xiu Li Zuo, Yan Qing Li. Susceptibility‐guided quadruple therapy is not superior to medication history‐guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial. Journal of Digestive Diseases 2020; 21(10): 549 doi: 10.1111/1751-2980.12934
|
25 |
Qiuyue Huang, Zongming Shi, Hong Cheng, Hui Ye, Xuezhi Zhang. Efficacy and Safety of Modified Dual Therapy as the First-line Regimen for the Treatment of Helicobacter pylori Infection. Journal of Clinical Gastroenterology 2021; 55(10): 856 doi: 10.1097/MCG.0000000000001448
|
26 |
Cláudia Sousa, Rute Ferreira, Nuno F. Azevedo, Mónica Oleastro, Joana Azeredo, Ceu Figueiredo, Luís D. R. Melo. Helicobacter pylori infection: from standard to alternative treatment strategies. Critical Reviews in Microbiology 2022; 48(3): 376 doi: 10.1080/1040841X.2021.1975643
|
27 |
Xiaoqi Wu, Miao Duan, Qingzhou Kong, Shuyan Zeng, Leiqi Xu, Yueyue Li, Xiaoyun Yang, Xiuli Zuo. Clarifying varied Helicobacter pylori eradication therapies: A comprehensive review. Helicobacter 2024; 29(1) doi: 10.1111/hel.13048
|
28 |
L.F. Garrido-Treviño, M. López-Martínez, J.A. Flores-Hinojosa, L. Tijerina-Rodríguez, F. Bosques-Padilla. Empiric treatment vs susceptibility-guided treatment for eradicating H. pylori: Is it possible to change that paradigm using modern molecular methods?. Revista de Gastroenterología de México (English Edition) 2022; 87(3): 330 doi: 10.1016/j.rgmxen.2022.06.003
|
29 |
Xiaoye Shi, Chunmei Wang, Fanjun Meng, Shaoze Ma, Guangqin Xu, Tingwei Liu, Xiaozhong Guo, Hongyu Li, Xingshun Qi. Impact of insufficient doses of medications on Helicobacter pylori eradication: a retrospective observational study. Postgraduate Medicine 2022; 134(7): 668 doi: 10.1080/00325481.2022.2105094
|
30 |
Karolina Kasza, Pratik Gurnani, Kim R. Hardie, Miguel Cámara, Cameron Alexander. Challenges and solutions in polymer drug delivery for bacterial biofilm treatment: A tissue-by-tissue account. Advanced Drug Delivery Reviews 2021; 178: 113973 doi: 10.1016/j.addr.2021.113973
|
31 |
Kiarash Ghazvini, Hossein Kamali, Seyed-Abolfazl Hosseininasab-nodoushan, Masoud Keikha. The CYP2C19 polymorphisms effects on H. pylori cure rate in proton pump inhibitor-based therapeutic regimens: An updated meta-analysis. Gene Reports 2021; 25: 101340 doi: 10.1016/j.genrep.2021.101340
|
32 |
Jin Young Yoon, Min Seob Kwak, Jung Won Jeon, Jae Myung Cha. Pretreatment with Ranitidine Bismuth Citrate May Improve Success Rates of <i>Helicobacter pylori</i> Eradication: A Prospective, Randomized, Controlled and Open-Label Study. The Tohoku Journal of Experimental Medicine 2021; 255(1): 41 doi: 10.1620/tjem.255.41
|
33 |
Nataliya V. Yakovleva, Galina I. Smirnova, Anatoliy A. Korsunsky. Modern aspects of Helicobacter pylori infection. Russian Pediatric Journal 2023; 26(1): 67 doi: 10.46563/1560-9561-2023-26-1-67-74
|
34 |
Ozgur KARCIOGLU, Selman YENİOCAK, Mandana HOSSEINZADEH, Seckin Bahar SEZGIN. Abdominal Pain: Essential Diagnosis and Management in Acute Medicine. 2022; : 51 doi: 10.2174/9789815051780122010005
|
35 |
Erick A. Argueta, Steven F. Moss. How We Approach Difficult to Eradicate Helicobacter pylori. Gastroenterology 2022; 162(1): 32 doi: 10.1053/j.gastro.2021.10.048
|
36 |
Heloisa B. Assalin, Kelly Cristiane Gabriel De Almeida, Dioze Guadagnini, Andrey Santos, Caio J. Teixeira, Silvana Bordin, Guilherme Z. Rocha, Mario J. A. Saad. Proton Pump Inhibitor Pantoprazole Modulates Intestinal Microbiota and Induces TLR4 Signaling and Fibrosis in Mouse Liver. International Journal of Molecular Sciences 2022; 23(22): 13766 doi: 10.3390/ijms232213766
|
37 |
Wenwen Gao, Xiang Zhang, Yanhui Yin, Shuwen Yu, Lu Wang. Different dose of new generation proton pump inhibitors for the treatment ofHelicobacter pyloriinfection: A meta-analysis. International Journal of Immunopathology and Pharmacology 2021; 35: 205873842110303 doi: 10.1177/20587384211030397
|
38 |
Pakkapon Rattanachaisit, Chuti Burana, Aunchalee Jaroenlapnopparat, Sirikorn Vongseenin, Supakarn Chaithongrat, Rungsun Rerknimitr, Duangporn Werawatganon. The prevalence and treatment outcomes of Helicobacter pylori infection in a tertiary hospital in Thailand, 2018–2021. JGH Open 2023; 7(6): 439 doi: 10.1002/jgh3.12916
|
39 |
Giuseppe Losurdo, Natale Lino Bruno Caccavo, Giuseppe Indellicati, Francesca Celiberto, Enzo Ierardi, Michele Barone, Alfredo Di Leo. Effect of Long-Term Proton Pump Inhibitor Use on Blood Vitamins and Minerals: A Primary Care Setting Study. Journal of Clinical Medicine 2023; 12(8): 2910 doi: 10.3390/jcm12082910
|
40 |
Dita Gudra, Ivars Silamikelis, Janis Pjalkovskis, Ilva Danenberga, Darta Pupola, Girts Skenders, Maija Ustinova, Kaspars Megnis, Marcis Leja, Reinis Vangravs, Davids Fridmanis, Iddya Karunasagar. Abundance and prevalence of ESBL coding genes in patients undergoing first line eradication therapy for Helicobacter pylori. PLOS ONE 2023; 18(8): e0289879 doi: 10.1371/journal.pone.0289879
|
41 |
Manuel Pabón‐Carrasco, Alma Keco‐Huerga, Manuel Castro‐Fernández, Ilaria Maria Saracino, Giulia Fiorini, Dino Vaira, Ángeles Pérez‐Aísa, Bojan Tepes, Laimas Jonaitis, Irina Voynovan, Alfredo J. Lucendo, Ángel Lanas, Samuel J. Martínez‐Domínguez, Enrique Alfaro Almajano, Luis Rodrigo, Ludmila Vologzanina, Natasa Brglez Jurecic, Maja Denkovski, Luis Bujanda, Rustam A. Abdulkhakov, Jose M. Huguet, Luis Fernández‐Salazar, Noelia Alcaide, Benito Velayos, Aiman Silkanovna Sarsenbaeva, Oleg Zaytsev, Tatiana Ilchishina, Jesús Barrio, Igor Bakulin, Monica Perona, Sergey Alekseenko, Marco Romano, Antonietta G. Gravina, Óscar Núñez, Blas José Gómez Rodríguez, Diego Ledro‐Cano, Rinaldo Pellicano, Pavel Bogomolov, Manuel Domínguez‐Cajal, Pedro Almela, Judith Gomez‐Camarero, Dmitry S. Bordin, Antonio Gasbarrini, Juozas Kupčinskas, Anna Cano‐Català, Leticia Moreira, Olga P. Nyssen, Francis Mégraud, Colm O’Morain, Javier P. Gisbert. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management. United European Gastroenterology Journal 2024; 12(1): 122 doi: 10.1002/ueg2.12476
|
42 |
Ana C. P. Correia, Danielle Straub, Silvia Calpe, Kausilia K. Krishnadath. Novel In Vivo Mouse Cryoablation Model to Explore Unique Therapeutic Approaches for Premalignant Columnar Lesions. Methods and Protocols 2021; 4(1): 6 doi: 10.3390/mps4010006
|
43 |
XinBo Xu, Cong He, Yin Zhu. Treatment of refractory Helicobacter pylori infection: A new challenge for clinicians. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.998240
|
44 |
Ana Bačić, Vladimir Milivojević, Isidora Petković, Dušan Kekić, Ina Gajić, Branislava Medić Brkić, Dušan Popadić, Tomica Milosavljević, Mirjana Rajilić-Stojanović. In Search for Reasons behind Helicobacter pylori Eradication Failure–Assessment of the Antibiotics Resistance Rate and Co-Existence of Helicobacter pylori with Candida Species. Journal of Fungi 2023; 9(3): 328 doi: 10.3390/jof9030328
|
45 |
L.F. Garrido-Treviño, M. López-Martínez, J.A. Flores-Hinojosa, L. Tijerina-Rodríguez, F. Bosques-Padilla. Tratamiento empírico vs tratamiento basado en susceptibilidad para erradicar H.pylori: ¿es posible cambiar este paradigma usando métodos moleculares modernos?. Revista de Gastroenterología de México 2022; 87(3): 330 doi: 10.1016/j.rgmx.2022.01.007
|
46 |
Hassan Seddik, Jihane Benass, Sanaa Berrag, Asmae Sair, Reda Berraida, Hanae Boutallaka. Optimized sequential therapy <i>vs</i> 10- and 14-d concomitant therapy for eradicating <i>Helicobacter pylori</i>: A randomized clinical trial. World Journal of Gastroenterology 2024; 30(6): 556-564 doi: 10.3748/wjg.v30.i6.556
|
47 |
Hyeonsoo Park, Choon Ok Kim, Mikyung Kim, Yeji Lim, Woo Yul Lee, Sukyong Yoon, Min Soo Park. Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects. Translational and Clinical Pharmacology 2020; 28(3): 136 doi: 10.12793/tcp.2020.28.e16
|
48 |
Yatin Lunagariya, Mit Shah, Saiprasad Lad, Shamshersingh Chauhan, Vikramaditya Rawat, Yogesh Bairwa, Chintan Tailor, Vinay Borkar, Shivani Chopra, Deepak Sasikumar, Meghraj Ingle. Comparing Short-Term Dual vs Standard Quadruple Therapy for Helicobacter pylori Eradication. American Journal of Gastroenterology 2024; doi: 10.14309/ajg.0000000000002882
|